BTIG Reaffirms Buy Rating for Edwards Lifesciences

BTIG reiterated its buy rating for Edwards Lifesciences Corporation (NYSE:EW) on June 30, 2026, setting a price target of $110. Analyst Marie Thibault maintained her optimistic stance on the medical device company, reinforcing the firm's confidence in its growth prospects.

Other Institutional Activity in Edwards Lifesciences

BlackRock, Inc. increased its holdings in Edwards Lifesciences by 129,018 shares, bringing its total to 52,590,933 shares valued at approximately $4.21 billion. Vanguard Capital Management LLC opened a new position with 37,727,792 shares worth around $3.02 billion. Similarly, Vanguard Portfolio Management LLC also initiated a stake, acquiring 26,407,018 shares valued at about $2.11 billion. State Street Corp added 304,875 shares, ending with 26,296,399 shares valued at $2.11 billion. Wellington Management Group LLP increased its stake by 217,152 shares, bringing its total to 22,011,101 shares worth $1.76 billion. Conversely, JPMorgan Chase & Co reduced its holdings by 4,280,140 shares, leaving it with 21,744,712 shares valued at $1.73 billion.

Edwards Lifesciences Corporation Stock Up 0.3%

Shares of NYSE:EW traded near $91.18 on Tuesday. Edwards Lifesciences has a market cap of approximately $52.3 billion and a P/E ratio of 49.07. The company's stock has a 52-week low of $72.30 and a high of $92.46, with a 50-day moving average of $84.29 and a 200-day moving average of $82.16. The firm maintains a robust financial position with a current ratio of 4.42 and a quick ratio of 3.30.

Recent Earnings

In its most recent earnings report, Edwards Lifesciences posted revenue of about $6.30 billion, reflecting a growth of 16.7%. The company's net margin stood at 17.39%, with a return on equity of 10.46%. Earnings per share were reported at $1.85. The next earnings announcement is expected on July 23, 2026.

Insider Buying and Selling at Edwards Lifesciences Corporation

Recent insider activity at Edwards Lifesciences included several stock sales. CEO Bernard Zovighian sold 523 shares at an average price of $87.92 on June 17, 2026, under a planned transaction. SVP Corporate Controller Andrew Dahl sold 568 shares at $86.08 on May 29, 2026. CVP of Strategy and Corporate Development Donald Bobo Jr. sold 23,145 shares at $86.42 on May 27, 2026. CVP of TMTT & Surgical Daveen Chopra sold 1,500 shares at $84.60 on May 22, 2026. CVP of TAVR Daniel Lippis made both a purchase and a sale on May 18, 2026, buying 620 shares at $72.68 and selling the same amount at $0.00.

Analysts Set New Price Targets

On June 30, 2026, BTIG maintained its buy rating on Edwards Lifesciences with a price target of $110. RBC Capital reiterated its buy rating with a $100 target on June 16, 2026. TD Cowen also maintained a buy rating with a $104 target on June 2, 2026. The consensus among 26 analysts is a buy recommendation, with a mean target price of $96.92.

About Edwards Lifesciences

Edwards Lifesciences Corporation, headquartered in Irvine, California, specializes in providing medical devices and technologies for treating advanced cardiovascular diseases. The company is known for its transcatheter heart valve replacement products under the Edwards SAPIEN family and offers solutions for mitral and tricuspid valve diseases with its PASCAL and EVOQUE brands. Founded in 1958, Edwards Lifesciences employs about 16,000 people and operates globally.

Bottom Line

BTIG's reaffirmation of its buy rating for Edwards Lifesciences, alongside a $110 price target, highlights continued confidence in the company's growth trajectory. Investors often monitor such analyst updates for insights into potential future performance, though it's important to remember these are based on past data and projections. Edwards Lifesciences remains a key player in the healthcare sector, with its innovative cardiovascular solutions.